ATE277608T1 - 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen - Google Patents
2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungenInfo
- Publication number
- ATE277608T1 ATE277608T1 AT01943761T AT01943761T ATE277608T1 AT E277608 T1 ATE277608 T1 AT E277608T1 AT 01943761 T AT01943761 T AT 01943761T AT 01943761 T AT01943761 T AT 01943761T AT E277608 T1 ATE277608 T1 AT E277608T1
- Authority
- AT
- Austria
- Prior art keywords
- closed head
- inhibitor
- necrosis factor
- tumor necrosis
- neuroprotector
- Prior art date
Links
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 title abstract 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 4
- 208000018652 Closed Head injury Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title 1
- 230000001067 neuroprotector Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 2
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 206010030113 Oedema Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007971 neurological deficit Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21370500P | 2000-06-23 | 2000-06-23 | |
| PCT/IL2001/000551 WO2001097793A2 (en) | 2000-06-23 | 2001-06-17 | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277608T1 true ATE277608T1 (de) | 2004-10-15 |
Family
ID=22796176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01943761T ATE277608T1 (de) | 2000-06-23 | 2001-06-17 | 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6566543B2 (de) |
| EP (1) | EP1292288B1 (de) |
| JP (1) | JP2003535892A (de) |
| AT (1) | ATE277608T1 (de) |
| AU (1) | AU2001266289A1 (de) |
| DE (1) | DE60106026T2 (de) |
| ES (1) | ES2227220T3 (de) |
| WO (1) | WO2001097793A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20030842B1 (hr) * | 2001-05-25 | 2017-06-02 | Ares Trading S.A. | UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a |
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2004103410A1 (en) | 2002-06-06 | 2004-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods compositions and articles of manufacture for modulating bone growth |
| GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
| GB2442161B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Triglycerides |
| GB2422373B (en) | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| GB0319358D0 (en) * | 2003-08-18 | 2003-09-17 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| GB2442164B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Treatment of neurodegenerative conditions |
| JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
| GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
| GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
| WO2008081989A1 (ja) | 2006-12-28 | 2008-07-10 | Suntory Holdings Limited | 神経再生剤 |
| EP2205240A1 (de) * | 2007-10-02 | 2010-07-14 | Ariel-University Research And Development Company, Ltd. | Endocannabinoide zur verstärkung von wachstum und entwicklung bei kleinkindern |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| US20200069618A1 (en) * | 2018-09-04 | 2020-03-05 | John C. Gustin | Compositions having an agent and an enhancer thereof, methods of use, and delivery systems |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1247165B (it) * | 1991-03-15 | 1994-12-12 | Fidia Spa | Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie. |
| US5456912A (en) * | 1993-12-28 | 1995-10-10 | The Regents Of The University Of California | Non-methylene interrupted fatty acids as immunomodulators |
| WO1999051560A1 (en) * | 1998-04-03 | 1999-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic endogenous cannabinoids analogues and uses thereof |
-
2001
- 2001-06-17 EP EP01943761A patent/EP1292288B1/de not_active Expired - Lifetime
- 2001-06-17 DE DE60106026T patent/DE60106026T2/de not_active Expired - Fee Related
- 2001-06-17 ES ES01943761T patent/ES2227220T3/es not_active Expired - Lifetime
- 2001-06-17 AU AU2001266289A patent/AU2001266289A1/en not_active Abandoned
- 2001-06-17 AT AT01943761T patent/ATE277608T1/de not_active IP Right Cessation
- 2001-06-17 WO PCT/IL2001/000551 patent/WO2001097793A2/en not_active Ceased
- 2001-06-17 JP JP2002503270A patent/JP2003535892A/ja active Pending
- 2001-06-22 US US09/887,745 patent/US6566543B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2227220T3 (es) | 2005-04-01 |
| US20020072539A1 (en) | 2002-06-13 |
| WO2001097793A2 (en) | 2001-12-27 |
| WO2001097793A3 (en) | 2003-01-09 |
| JP2003535892A (ja) | 2003-12-02 |
| DE60106026T2 (de) | 2006-02-23 |
| DE60106026D1 (de) | 2004-11-04 |
| EP1292288A2 (de) | 2003-03-19 |
| AU2001266289A1 (en) | 2002-01-02 |
| EP1292288B1 (de) | 2004-09-29 |
| US6566543B2 (en) | 2003-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60106026D1 (de) | 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen | |
| TW200635588A (en) | 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof | |
| WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
| WO2004004661A3 (en) | Boroproline compound combination therapy | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| TNSN04113A1 (en) | 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| BR0317747A (pt) | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave | |
| DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| BR0317020A (pt) | Derivados de hidroxietilamina para o tratamento de doença de alzheimer | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| WO2006078424A3 (en) | Polyherbal compositions and methods for treating viral infections | |
| DE69400353D1 (de) | Schlankmachende Zusammensetzung | |
| WO2002079169A8 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| TNSN06403A1 (en) | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
| PT1562954E (pt) | Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a. | |
| WO2002079149A3 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |